NUVL

Nuvalent, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001861560

$100.45 -1.83% $8.1B

Insider Selling Cluster (4 insiders)High Impact Filing (7/10)

Vol

Market Cap$8.1B

Cap SizeMid Cap

Analyst ConsensusStrong Buy (96%)

Inst. Holders7 funds

Inst. Value$1.8B

Inst. Activity2 buys / 0 sells

Insider Activity0B / 15S

Insider Net $-$9.0M

SEC Reports10

Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001861560·Prev Close $102.32

Recent Activity

Sep 18, 2026 fda_pdufa

PDUFA: NUVL — zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC — 2026-09-18

FDA target action date 2026-09-18 for NUVL (Nuvalent, Inc.). Drug: zidesamtinib. Indication: TKI pre

May 7, 2026 SEC

Nuvalent reported Q1 2026 results with a net loss of $109.3M ($1.39/share), wider than the $84.6M loss in Q1 2025, as R&

8-K — Impact 4/10

May 5, 2026 SEC

Three Nuvalent insiders (CFO, CLO, CDO) sold a total of ~$1.27M in open-market shares over three days, with all sales ti

CLUSTER — Impact 2/10

May 4, 2026 Insider

Porter James Richard sold 1,699 shares

President and CEO @ $98.54 ($167.4K)

May 4, 2026 Insider

Porter James Richard sold 30,000 shares

President and CEO @ $18.93 ($567.9K)

May 4, 2026 Insider

Porter James Richard sold 30,000 shares

President and CEO @ $0.00 ($0.00)

Apr 13, 2026 SEC

Nuvalent CEO and Chief Scientific Officer sold shares worth $1.4M in the past week, including a $1.17M open-market sale

CLUSTER — Impact 6/10

Inst.

NORGES BANK — NEW

574,242 shares ($57.8M)

Price Targets

$142.05 +41.4% upside Strong Buy

Current $100.45 Low $116.00 Median $141.00 High $165.00 18 analysts

$116.00 $165.00

Analyst Ratings

Strong Buy96% buy · 25 analysts

8Strong Buy

16Buy

1Hold

0Sell

0Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
Apr 21, 2026	HC Wainwright & Co.	REITERATE	Buy → Buy
Apr 8, 2026	Wedbush	REITERATE	Outperform → Outperform
Mar 30, 2026	Wells Fargo	INITIATE	Overweight
Feb 27, 2026	Cantor Fitzgerald	MAINTAIN	Overweight → Overweight
Dec 19, 2025	JP Morgan	MAINTAIN	Overweight → Overweight

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-1.38	$-1.53 — $-1.13	1% YoY	16
Next Q	$-1.40 ▼ -0.5%	$-1.65 — $-1.21	18% YoY	16
Current FY	$-5.45 ▲ +0.9%	$-6.37 — $-4.66	7% YoY	16
Next FY	$-3.99 ▲ +1.1%	$-6.83 — $-1.06	27% YoY	16

Latest Reports

NEUTRAL 8-K 4/10

Nuvalent reported Q1 2026 results with a net loss of $109.3M ($1.39/share), wider than the $84.6M loss in Q1 2025, as R&

May 7, 2026

NEUTRAL CLUSTER 2/10

Three Nuvalent insiders (CFO, CLO, CDO) sold a total of ~$1.27M in open-market shares over three days, with all sales ti

May 5, 2026

Top Institutional Holders

Fund	Value	Move
FMR LLC	$1.1B	—
VANGUARD GROUP INC	$527.5M	—
NORGES BANK	$57.8M	NEW
CHARLES SCHWAB INVESTMENT MANAGEMENT	$45.6M	NEW
MORGAN STANLEY	$26.9M	TRIM

Recent Insider Trades

Date	Insider	Type	Value
May 4, 2026	Porter James	SELL	$167.4K
May 4, 2026	Porter James	M	$567.9K
May 4, 2026	Porter James	M	$0.00
May 1, 2026	Balcom Alexandra	M	$7.7K
May 1, 2026	Balcom Alexandra	M	$0.00

7 institutional holders with $1.8B total value (17,634,621 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, NORGES. Net buying activity: 2 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	FMR LLC	10,852,884	$1.1B	61.5%	—
2	VANGUARD GROUP INC	5,244,271	$527.5M	29.7%	—
3	NORGES BANK	574,242	$57.8M	3.3%	NEW
4	CHARLES SCHWAB INVESTMENT MANAGEMENT INC	453,311	$45.6M	2.6%	NEW
5	MORGAN STANLEY	267,389	$26.9M	1.5%	TRIM -34.9%
6	BANK OF AMERICA CORP /DE/	180,369	$18.1M	1.0%	TRIM -37.5%
7	WELLS FARGO & COMPANY/MN	62,155	$6.3M	0.4%	DOUBLED +101.3%

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
NORGES BANK	NEW	—	574,242	—	$57.8M	2025-Q4
WELLS FARGO & COMPANY/MN	DOUBLED	30,872	62,155	+101.3%	$6.3M	2025-Q4
MORGAN STANLEY	TRIM	422,722	275,110	-34.9%	$23.8M	2025-Q3
UBS Group AG	ADD	136,744	213,121	+55.9%	$18.4M	2025-Q3
BANK OF AMERICA CORP /DE/	TRIM	257,940	161,186	-37.5%	$13.9M	2025-Q3
WELLS FARGO & COMPANY/MN	TRIM	42,975	30,872	-28.2%	$2.7M	2025-Q3
NORGES BANK	EXIT	374,597	0	-100.0%	$0.00	2025-Q3
RENAISSANCE TECHNOLOGIES LLC	EXIT	29,200	0	-100.0%	$0.00	2025-Q3
TWO SIGMA INVESTMENTS, LP	EXIT	8,959	0	-100.0%	$0.00	2025-Q3
NORGES BANK	NEW	—	374,597	—	$28.6M	2025-Q2
WELLS FARGO & COMPANY/MN	DOUBLED	21,457	42,975	+100.3%	$3.3M	2025-Q2
TWO SIGMA INVESTMENTS, LP	NEAR_EXIT	159,123	8,959	-94.4%	$683.6K	2025-Q2
MORGAN STANLEY	ADD	222,284	348,080	+56.6%	$24.7M	2025-Q1
TWO SIGMA INVESTMENTS, LP	TRIM	213,882	159,123	-25.6%	$11.3M	2025-Q1
CITADEL ADVISORS LLC	TRIM	241,095	133,800	-44.5%	$9.5M	2025-Q1
UBS Group AG	ADD	54,840	109,479	+99.6%	$7.8M	2025-Q1
RENAISSANCE TECHNOLOGIES LLC	DOUBLED	9,100	28,700	+215.4%	$2.0M	2025-Q1
NORGES BANK	EXIT	318,739	0	-100.0%	$0.00	2025-Q1
CITADEL ADVISORS LLC	TRIM	383,558	241,095	-37.1%	$18.9M	2024-Q4
MORGAN STANLEY	TRIM	471,717	222,284	-52.9%	$17.4M	2024-Q4
WELLS FARGO & COMPANY/MN	ADD	16,025	21,220	+32.4%	$1.7M	2024-Q4
RENAISSANCE TECHNOLOGIES LLC	NEW	—	9,100	—	$712.3K	2024-Q4
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	NEW	—	315,827	—	$32.3M	2024-Q3

6 unique insiders with 15 transactions. Net insider value: -$9.0M ($0.00 bought, $9.0M sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
May 4, 2026	Porter James Richard	President and CEO	SELL	1,699	$98.54	$167.4K
May 4, 2026	Porter James Richard	President and CEO	M	30,000	$18.93	$567.9K
May 4, 2026	Porter James Richard	President and CEO	M	30,000	$0.00	$0.00
May 1, 2026	Balcom Alexandra	Chief Financial Officer	M	7,159	$1.08	$7.7K
May 1, 2026	Balcom Alexandra	Chief Financial Officer	M	7,159	$0.00	$0.00
May 1, 2026	Balcom Alexandra	Chief Financial Officer	SELL	3,872	$98.42	$381.1K
Apr 30, 2026	Miller Deborah Ann	Chief Legal Officer	M	5,500	$6.89	$37.9K
Apr 30, 2026	Miller Deborah Ann	Chief Legal Officer	SELL	4,418	$99.13	$438.0K
Apr 30, 2026	Miller Deborah Ann	Chief Legal Officer	M	5,500	$0.00	$0.00
Apr 29, 2026	Noci Darlene	Chief Development Officer	M	5,500	$27.85	$153.2K
Apr 29, 2026	Noci Darlene	Chief Development Officer	SELL	4,500	$99.35	$447.1K
Apr 29, 2026	Noci Darlene	Chief Development Officer	M	5,500	$0.00	$0.00
Apr 9, 2026	Pelish Henry E.	Chief Scientific Officer	M	3,093	$27.85	$86.1K
Apr 9, 2026	Pelish Henry E.	Chief Scientific Officer	SELL	2,193	$104.27	$228.7K
Apr 9, 2026	Pelish Henry E.	Chief Scientific Officer	M	3,093	$0.00	$0.00
Apr 6, 2026	Porter James Richard	President and CEO	M	13,714	$0.00	$0.00
Apr 6, 2026	Porter James Richard	President and CEO	M	13,714	$18.93	$259.6K
Apr 6, 2026	Porter James Richard	President and CEO	SELL	11,354	$103.21	$1.2M
Apr 1, 2026	Lane Benjamin	See Remarks	A	9,500	$0.00	$0.00
Apr 1, 2026	Lane Benjamin	See Remarks	A	19,000	$0.00	$0.00
Apr 1, 2026	Balcom Alexandra	Chief Financial Officer	M	11,430	$1.08	$12.3K
Apr 1, 2026	Balcom Alexandra	Chief Financial Officer	M	11,430	$0.00	$0.00
Apr 1, 2026	Balcom Alexandra	Chief Financial Officer	SELL	3,544	$104.39	$370.0K
Mar 30, 2026	Noci Darlene	Chief Development Officer	M	5,500	$27.85	$153.2K
Mar 30, 2026	Noci Darlene	Chief Development Officer	SELL	2,532	$97.43	$246.7K
Mar 30, 2026	Noci Darlene	Chief Development Officer	M	5,500	$0.00	$0.00
Mar 26, 2026	Miller Deborah Ann	Chief Legal Officer	M	5,500	$0.00	$0.00
Mar 26, 2026	Miller Deborah Ann	Chief Legal Officer	M	5,500	$6.89	$37.9K
Mar 26, 2026	Miller Deborah Ann	Chief Legal Officer	SELL	940	$97.50	$91.7K
Mar 25, 2026	Balcom Alexandra	Chief Financial Officer	SELL	13,700	$100.16	$1.4M
Mar 24, 2026	Balcom Alexandra	Chief Financial Officer	M	11,430	$1.08	$12.3K
Mar 24, 2026	Balcom Alexandra	Chief Financial Officer	SELL	2,599	$95.03	$247.0K
Mar 24, 2026	Balcom Alexandra	Chief Financial Officer	M	11,430	$0.00	$0.00
Mar 13, 2026	Pelish Henry E.	Chief Scientific Officer	SELL	804	$97.89	$78.7K
Mar 12, 2026	Pelish Henry E.	Chief Scientific Officer	SELL	24,189	$97.79	$2.4M
Mar 12, 2026	Pelish Henry E.	Chief Scientific Officer	M	8,456	$0.00	$0.00
Mar 12, 2026	Pelish Henry E.	Chief Scientific Officer	M	8,456	$18.93	$160.1K
Mar 6, 2026	Porter James Richard	President and CEO	M	30,000	$27.85	$835.5K
Mar 6, 2026	Porter James Richard	President and CEO	SELL	13,585	$98.59	$1.3M
Mar 6, 2026	Porter James Richard	President and CEO	M	30,000	$0.00	$0.00
Feb 26, 2026	Noci Darlene	Chief Development Officer	M	5,500	$27.85	$153.2K
Feb 26, 2026	Noci Darlene	Chief Development Officer	M	5,500	$0.00	$0.00
Feb 26, 2026	Miller Deborah Ann	Chief Legal Officer	M	5,500	$6.89	$37.9K
Feb 26, 2026	Miller Deborah Ann	Chief Legal Officer	M	5,500	$0.00	$0.00
Jan 29, 2026	Noci Darlene	Chief Development Officer	M	5,500	$0.00	$0.00
Jan 29, 2026	Noci Darlene	Chief Development Officer	SELL	189	$100.95	$19.1K
Jan 29, 2026	Noci Darlene	Chief Development Officer	M	5,500	$27.85	$153.2K

10 SEC filing reports analyzed. Sentiment: 2 bullish, 4 bearish, 0 mixed, 4 neutral. Avg impact: 5.3/10.

NEUTRAL 8-K 4/10

Nuvalent reported Q1 2026 results with a net loss of $109.3M ($1.39/share), wider than the $84.6M lo

May 7, 2026

NEUTRAL CLUSTER 2/10

Three Nuvalent insiders (CFO, CLO, CDO) sold a total of ~$1.27M in open-market shares over three day

May 5, 2026

BEARISH CLUSTER 6/10

Nuvalent CEO and Chief Scientific Officer sold shares worth $1.4M in the past week, including a $1.1

Apr 13, 2026

BEARISH CLUSTER 7/10

Nuvalent CEO and CFO sold shares worth $1.79M in a coordinated cluster over the past week, with the

Apr 8, 2026

BULLISH 8-K 7/10

Nuvalent, Inc. announced the submission of its New Drug Application (NDA) to the U.S. FDA for nelada

Apr 7, 2026

NEUTRAL CLUSTER 3/10

Three Nuvalent executives, including the CFO and Chief Development Officer, sold shares in a coordin

Apr 3, 2026

BEARISH CLUSTER 7/10

Three C-suite executives at Nuvalent sold a combined $1.71M in shares over a 7-day period, including

Apr 1, 2026

BEARISH CLUSTER 6/10

Analysis based on filing metadata only — document content was unavailable. Cross-filing context reve

Mar 30, 2026

NEUTRAL CLUSTER 4/10

Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 24,993 shares in open-market transactions

Mar 16, 2026

BULLISH 8-K 7/10

Nuvalent reported its 2025 financial results, highlighted a strong cash position of $1.4 billion wit

Feb 26, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (96% buy). Based on 25 analysts: 8 strong buy, 16 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$142.05 mean target +41.4% upside Strong Buy (1.21)

$116.00 Low $165.00 High

Metric	Value
Current Price	$100.45
Target Low	$116.00
Target Mean	$142.05
Target Median	$141.00
Target High	$165.00
# Analysts	18
Recommendation	Strong Buy (1.21)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-1.38	$-1.53	$-1.13	1.0%	-0.3%	6↑ 6↓	$0.0B	0.0%	16
Next Q 2026-09-30	$-1.40	$-1.65	$-1.21	17.8%	-0.5%	6↑ 6↓	$0.0B	0.0%	16
Current FY 2026-12-31	$-5.45	$-6.37	$-4.66	6.8%	+0.9%	7↑ 7↓	$0.0B	0.0%	16
Next FY 2027-12-31	$-3.99	$-6.83	$-1.06	26.8%	+1.1%	5↑ 8↓	$0.2B	1333.4%	16

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-1.376
7d ago	$-1.384	+0.008
30d ago	$-1.372	-0.004
60d ago	$-1.373	-0.002
90d ago	$-1.496	+0.120

6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Apr 21, 2026	HC Wainwright & Co.	REITERATE	Buy	Buy
Apr 8, 2026	Wedbush	REITERATE	Outperform	Outperform
Mar 30, 2026	Wells Fargo	INITIATE	—	Overweight
Feb 27, 2026	Cantor Fitzgerald	MAINTAIN	Overweight	Overweight
Dec 19, 2025	JP Morgan	MAINTAIN	Overweight	Overweight
Nov 24, 2025	Truist Securities	INITIATE	—	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
May 1, 2026	8	16	1	96%
Apr 1, 2026	8	15	1	96%
Mar 1, 2026	8	15	1	96%
Feb 1, 2026	8	15	1	96%
Jan 1, 2026	8	15	1	96%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Sep 18, 2026

fda_pdufa

PDUFA: NUVL — zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC — 2026-09-18

FDA target action date 2026-09-18 for NUVL (Nuvalent, Inc.). Drug: zidesamtinib. Indication: TKI pre-treated advanced ROS1-positive NSCLC. FDA assigne

May 7, 2026

earnings_calendar

NUVL Q1 2026 Earnings Scheduled — 2026-05-07

May 6, 2026

earnings_calendar

NUVL Q1 2026 Earnings Scheduled — 2026-05-06

Mar 4, 2026

earnings_calendar

NUVL Q4 2025 Earnings After Market Close — 2026-03-04

Feb 4, 2026

short_interest

FTD: NUVL — 7,149 shares ($0.8M) failed to deliver

Settlement: 20260204, Price: $107.17, FTD Value: $766,158.33, NUVALENT INC CL A (DE)

Feb 2, 2026

short_interest

FTD: NUVL — 5,588 shares ($0.6M) failed to deliver

Settlement: 20260202, Price: $102.89, FTD Value: $574,949.32, NUVALENT INC CL A (DE)